Localization of RANKL (receptor activator of NFκB ligand) mRNA and protein in skeletal and extraskeletal tissues

Bone

Volumn 25, Issue 5, 1999, Pages 525-534

  Kartsogiannis, V ^a   Zhou, H ^a   Horwood, N J ^a   Thomas, R J ^a   Hards, D K ^a   Quinn, J M W ^a   Niforas, P ^a   Ng, K W ^a   Martin, T J ^a   Gillespie, M T ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Endochondral bone; Immunohistochemistry; In situ hybridization; Intramembranous bone; ODF; TRANCE

Indexed keywords

ACID PHOSPHATASE; MESSENGER RNA; PROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE TUMOR; BRAIN; CARTILAGE CELL; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; ENCHONDRAL OSSIFICATION; GIANT CELL TUMOR; HEART; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTESTINE; KIDNEY; LIVER; LONG BONE; LUNG; MALE; MEGAKARYOCYTE; MESENCHYME; MOUSE; NEWBORN; OSTEOBLAST; OSTEOCLAST; PERIOSTEUM; PROTEIN EXPRESSION; RABBIT; SKELETAL MUSCLE; SKELETON; SKIN; TISSUE DISTRIBUTION;

AMINO ACID SEQUENCE; ANIMALS; BONE AND BONES; BONE DEVELOPMENT; BONE MARROW; CARRIER PROTEINS; FEMALE; GIANT CELL TUMOR OF BONE; GIANT CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; ORGAN SPECIFICITY; OSTEOBLASTS; OSTEOCLASTS; PREGNANCY; RABBITS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RNA, MESSENGER; SPECIES SPECIFICITY;

EID: 0032836854     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(99)00214-8     Document Type: Article

References (41)

1. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D., Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 390:1997;175-179.
2. Athanasou N.A., Quinn J.M.W. Bone resorption by macrophage polykaryons of a pilar tumor of scalp. Cancer. 70:1992;469-475.
3. Athanasou N.A., Quinn J.M.W., Ferguson D.J.P., McGee J.O. 'D. Bone resorption by macrophage polykaryons of giant cell tumor of tendon sheath. Br J Cancer. 63:1991;527-533.
4. Athanasou N.A., Wells C.A., Quinn J.M.W., Ferguson D.J.P., Heryet A., McGee J.O. 'D. The origin and nature of stromal osteoclast like multinucleated giant cells in breast carcinoma implications for tumor osteolysis and macrophage biology . Br J Cancer. 59:1989;491-498.
5. Boenisch, T. Staining Methods. In: Naish, S. J., Ed. Handbook: Immunochemical Staining Methods. DAKOPATTS (Dako Corporation); 1989; 16-17.
6. Bolam J.P. Preparation of CNS tissue for light and electron microscopy. Bolam J.P. Experimental Neuroanatomy, A Practical Approach. 1992;2-7 Oxford University Press, Oxford, UK.
7. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H.L., Xu W., Lacey D.L., Boyle W.J., Simonet W.S. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12:1998;1260-1268.
8. Danks J.A., Ebeling P.R., Hayman J., Chou S.T., Moseley J.M., Dunlop J., Kemp B.E., Martin T.J. Parathyroid hormone-related protein immunohistochemical localization in cancers and in normal skin . J Bone Miner Res. 4:1989;273-278.
9. Danks J.A., McHale J.C., Clark S.P., Chou S.T., Scurry J.P., Ingleton P.M., Martin T.J. In situ hybridization of parathyroid hormone-related protein in normal skin, skin tumors, and gynecological cancers using digoxigenin-labeled probes and antibody enhancement. J Histochem Cytochem. 43:1995;5-10.
10. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., Dul E., Appelbaum E.R., Eichman C., DiPrinzio R., Dodds R.A., James I.E., Rosenberg M., Lee J.C., Young P.R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 273:1998;14363-14367.
11. Goldring S.R., Roelke M.S., Petrison K.K., Bhan A.K. Human giant cell tumors of bone identification and characterization of cell types. J Clin Invest. 79:1987;483-491.
12. Goldring S.R., Schiller A.L., Mankin H.J., Dayer J.M., Krane S.M. Characterization of cells from human giant cell tumors of bone. Clin Orthop. 204:1986;59-75.
13. Hofstetter W., Wetterwald A., Cecchini M.G., Mueller Ch., Felix R. Detection of transcripts and binding sites for colony-stimulating factor-1 during bone development. Bone. 17:1995;145-151.
14. Horton M.A., Lewis D., McNulty K., Pringle J.A., Chambers T.J. Monoclonal antibodies to osteoclastomas (giant cell bone tumors) definition of osteoclast-specific cellular antigens . Cancer Res. 45:1985;5663-5669.
15. Horton M.A., Pringle J.A., Chambers T.J. Identification of human osteoclasts with monoclonal antibodies. N Engl J Med. 312:1985;923-924.
16. Horwood N.J., Elliott J., Martin T.J., Gillespie M.T. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology. 139:1998;4743-4746.
17. Hu Y.S., Zhou H., Kartsogiannis V., Eisman J.A., Martin T.J., Ng K.W. Expression of rat homeobox gene, rHOX, in developing and adult tissues in mice and regulation of its mRNA expression in osteoblasts by bone morphogenetic protein 2 and parathyroid hormone-related protein. Mol Endocrinol. 12:1998;1721-1732.
18. Kartsogiannis V., Moseley J., McKelvie B., Chou S.T., Hards D.K., Ng K.W., Martin T.J., Zhou H. Temporal expression of PTHrP during endochondral bone formation in mouse and intramembranous bone formation in an in vivo rabbit model. Bone. 21:1997;385-392.
19. Kartsogiannis V., Udagawa N., Ng K.W., Martin T.J., Moseley J.M., Zhou H. Localization of parathyroid hormone-related protein in osteoclasts by in situ hybridization and immunohistochemistry. Bone. 22:1998;189-194.
20. Kong Y.-Y., Yoshida H., Sarosi I., Tan H.-L., Timms E., Capparelli C., Morony S., Oliveira-dos-Santos A.J., Van G., Itie A., Khoo W., Wakeham A., Dunstan C.R., Lacey D.L., Mak T.W., Boyle W.J., Penninger J.M. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 397:1999;315-323.
21. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:1998;165-176.
22. Martin T.J., Ng K.W. Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity. J Cell Biochem. 56:1994;357-366.
23. Martin T.J., Ng K.W., Suda T. Bone cell physiology. Endocrinol Metab Clin North Am. 18:1989;833-858.
24. Matsuzaki K., Udagawa N., Takahashi N., Yamaguchi K., Yasuda H., Shima N., Morinaga T., Toyama Y., Yabe Y., Higashio K., Suda T. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun. 246:1998;199-204.
25. Mbalaviele G., Nishimura R., Myoi A., Niewolna M., Reddy S.V., Chen D., Feng J., Roodman D., Mundy G.R., Yoneda T. Cadherin-6 mediates the heterotypic interactions between the hemopoietic osteoclast cell lineage and stromal cells in a murine model of osteoclast differentiation. J Cell Biol. 141:1998;1467-1476.
26. Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Yano K., Moringa T., Higashio K. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun. 253:1998;395-400.
27. Neale S., Kristelly R., Gundle R., Quinn J.M.W., Athanasou N.A. The giant cells in pigmented villonodular synovitis express an osteoclast phenotype. J Clin Pathol. 50:1997;605-608.
28. Quinn J.W.M., Elliott J., Gillespie M.T., Martin T.J. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology. 139:1998;4424-4427.
29. Sadhukhan R., Santhamma K.R., Reddy P., Peschon J.J., Black R.A., Sen I. Unaltered cleavage and secretion of angiotensin-converting enzyme in tumor necrosis factor-alpha-converting enzyme-deficient mice. J Biol Chem. 274:1999;10511-10516.
30. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Boyle W.J. Osteoprotegerin a novel secreted protein involved in the regulation of bone density . Cell. 89:1997;309-319.
31. Suda T., Takahashi N., Martin T.J. Modulation of osteoclast differentiation. Endocr Rev. 13:1992;66-80.
32. Suda T., Udagawa N., Nakamura I., Miyaura C., Takahashi N. Modulation of osteoclast differentiation by local factors. Bone. 17:(Suppl.):1995;87-91.
33. Takahashi N., Udagawa N., Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun. 256:1999;449-455.
34. Weaver D.R., Deeds J.D., Lee K., Segre G.V. Localization of parathyroid hormone-related peptide (PTHrP) and PTH/PTHrP receptor mRNAs in rat brain. Brain Res Mol Brain Res. 28:1995;296-310.
35. Wong B.R., Josien R., Lee S.Y., Sauter B., Li H.L., Steinman R.M., Choi Y. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med. 186:1997;2075-2080.
36. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett F.S. III, Frankel W.N., Lee S.Y., Choi Y. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem. 272:1997;25190-25194.
37. Yamaguchi K., Kinosaki M., Goto M., Kobayashi F., Tsuda E., Morinaga T., Higashio K. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem. 273:1998;5117-5123.
38. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T., Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG) a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro . Endocrinology. 139:1998;1329-1337.
39. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95:1998;3597-3602.
40. Zhou H., Choong P., McCarthy R., Chou S.T., Martin T.J., Ng K.W. In situ hybridization to show sequential expression of osteoblast gene markers during bone formation in vivo. J Bone Miner Res. 9:1994;1489-1499.
41. Zhou H., Choong P.F., Henderson S., Chou S.T., Aspenberg P., Martin T.J., Ng K.W. Marrow development and its relationship to bone formation in vivo a histological study using an implantable titanium device in rabbits . Bone. 17:1995;407-415.